Last reviewed · How we verify
capecitabine and mitomycin
At a glance
| Generic name | capecitabine and mitomycin |
|---|---|
| Also known as | capecitabine, mitomycin |
| Sponsor | IRCCS San Raffaele |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study (PHASE2)
- HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer (PHASE2)
- Adaptive Radiation in Anal Cancer (NA)
- REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation (PHASE2, PHASE3)
- Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11) (NA)
- Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- capecitabine and mitomycin CI brief — competitive landscape report
- capecitabine and mitomycin updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI